Broadcast Date: 
  • Time: 

Although it is one of the most common forms of lung cancer, non-small cell lung tumors remain difficult to treat with current therapies such as tyrosine kinase inhibitors. Efforts to develop new treatments include a focus on novel antibody modalities such as bispecific antibodies (BsAbs). While single agent therapeutic agents have been used to treat various cancers and can help some patients, often the diversity of pathological mechanisms can limit the sustained response. The multifactorial nature of tumors has sparked a growing interest in BsAbs, which are increasingly preferred due to their greater selectivity and efficacy for a broader distribution of patients.

In this GEN webinar, Mark Chiu, PhD, will present a process for selecting an EGFR x cMET bispecific antibody to treat patients with EGFR inhibitor-resistant non-small lung cancer. He will share a strategy for selecting the lead candidate using different in vitro cell based assays as part of a hit to lead selection process. During the webinar, you’ll learn about critical endpoints in in vitro cell-based assays that guide the selection of hits with the highest functional activity as well as strategies for selecting a bispecific format that effectively engages with both therapeutic targets.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Mark Chiu
Mark Chiu, PhD
Chief Scientific Officer
Tavotek Biotherapeutics